Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia

Ann Hematol. 2016 Jan;95(2):347-8. doi: 10.1007/s00277-015-2516-7. Epub 2015 Oct 3.

Authors

Walla A Alfaraj¹, David Cachia², Sudhakar Tummala², Sheeba K Thomas¹, Elisabet E Manasanch³

Affiliations

¹ Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.
² Department of Neurology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
³ Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA. [email protected].

PMID: 26432713
DOI: 10.1007/s00277-015-2516-7

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / administration & dosage
Dexamethasone / adverse effects*
Humans
Male
Middle Aged
Oligopeptides / administration & dosage
Oligopeptides / adverse effects*
Peripheral Nervous System Diseases / chemically induced*
Peripheral Nervous System Diseases / diagnosis
Rituximab / administration & dosage
Rituximab / adverse effects*
Severity of Illness Index*
Waldenstrom Macroglobulinemia / diagnosis
Waldenstrom Macroglobulinemia / drug therapy*

Substances

Oligopeptides
Rituximab
carfilzomib
Dexamethasone